Julia Elvin
Overview
Explore the profile of Julia Elvin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
533
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Richardson D, Quintanilha J, Danziger N, Li G, Sokol E, Schrock A, et al.
Clin Cancer Res
. 2024 Jul;
30(20):4644-4653.
PMID: 39078736
Purpose: The purpose of the study was to compare the effectiveness of PARP inhibitor maintenance therapy (mPARPi) in real-world practice by biomarker status [BRCA1/2 alterations (BRCAalt) and a homologous recombination...
2.
Haberberger J, Pegram W, Britt N, Schiavone K, Severson E, Sharaf R, et al.
Oncologist
. 2023 Aug;
29(1):e47-e58.
PMID: 37619245
The authors present a cohort of 661 young adult glioblastomas diagnosed using 2016 WHO World Health Organization Classification of Tumors of the Central Nervous System, utilizing comprehensive genomic profiling (CGP)...
3.
Hayes D, Herbst R, Myles J, Topalian S, Yohe S, Aronson N, et al.
JCO Precis Oncol
. 2022 Nov;
6:e2200454.
PMID: 36446042
Purpose: Immune checkpoint inhibition (ICI) therapy represents one of the great advances in the field of oncology, highlighted by the Nobel Prize in 2018. Multiple predictive biomarkers for ICI benefit...
4.
Severson E, Haberberger J, Hemmerich A, Huang R, Edgerly C, Schiavone K, et al.
Oncologist
. 2022 Nov;
28(1):e26-e35.
PMID: 36342081
Background: B-cell primary central nervous system (CNS) lymphoma (PCL) is diffuse large B-cell lymphoma (DLBCL) confined to the CNS. Less than 50% of patients with PCL achieve complete remission with...
5.
Margolis M, Janovitz T, Laird J, Mata D, Montesion M, Lee J, et al.
Mod Pathol
. 2022 Aug;
35(11):1618-1623.
PMID: 35970994
Activation of the tyrosine kinase receptor IGF1R is targetable with existing tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, but mutations in IGF1R have not been systematically characterized. Pan-cancer analysis of...
6.
Huang R, Xiao J, Pavlick D, Guo C, Yang L, Jin D, et al.
Clin Chem
. 2021 Oct;
67(11):1554-1566.
PMID: 34626187
Background: The amounts of circulating cell-free DNA (cfDNA) and circulating-tumor DNA (ctDNA) present in peripheral blood liquid biopsies can vary due to preanalytic/analytic variables. In this study, we examined the...
7.
Huang R, Severson E, Haberberger J, Duncan D, Hemmerich A, Edgerly C, et al.
Pathol Oncol Res
. 2021 Jul;
27:592997.
PMID: 34257540
Comprehensive genomic profiling (CGP) and immunohistochemistry (IHC) are important biomarker tools used for patients with non-small cell lung cancer (NSCLC) given the expanding number of standard-of-care therapies that require companion...
8.
Jacob J, Necchi A, Grivas P, Hughes M, Sanford T, Mollapour M, et al.
Urol Oncol
. 2021 Jul;
39(10):731.e1-731.e15.
PMID: 34215504
Background: Carcinoma of the urethra (UrthCa) is an uncommon Genitourinary (GU) malignancy that can progress to advanced metastatic disease. Methods: One hundred twenty-seven metastatic UrthCa underwent hybrid capture-based comprehensive genomic...
9.
Ramkissoon L, Pegram W, Haberberger J, Danziger N, Lesser G, Strowd R, et al.
Front Neurol
. 2020 Nov;
11:544680.
PMID: 33192972
Despite advances in systemic therapies for solid tumors, the development of brain metastases remains a significant contributor to overall cancer mortality and requires improved methods for diagnosing and treating these...
10.
Eskander R, Elvin J, Gay L, Ross J, Miller V, Kurzrock R
JCO Precis Oncol
. 2020 Oct;
4.
PMID: 33015532
Purpose: High-grade neuroendocrine cervical cancer (HGNECC) is an uncommon malignancy with limited therapeutic options; treatment is patterned after the histologically similar small-cell lung cancer (SCLC). To better understand HGNECC biology,...